CAS 328947-93-9

Lgd 2226

Description:

LGD-2226, also known by its chemical name and CAS number 328947-93-9, is a selective androgen receptor modulator (SARM) that has garnered attention in the fields of pharmacology and sports science. It is designed to selectively bind to androgen receptors in muscle and bone tissues, promoting anabolic activity while minimizing androgenic effects in other tissues, such as the prostate. This selectivity is a key characteristic that distinguishes SARMs from traditional anabolic steroids. LGD-2226 is often researched for its potential applications in muscle wasting diseases and osteoporosis, as it may enhance muscle mass and strength without the side effects commonly associated with steroids. The compound is typically administered orally and has a favorable pharmacokinetic profile, which may include a longer half-life compared to other SARMs. However, as with many research chemicals, the long-term effects and safety profile of LGD-2226 in humans are not fully understood, and it remains a subject of ongoing research and regulatory scrutiny.

Formula: C₁₄H₉F₉N₂O

InChI: InChI=1S/C14H9F9N2O/c15-12(16,17)5-25(6-13(18,19)20)7-1-2-10-8(3-7)9(14(21,22)23)4-11(26)24-10/h1-4H,5-6H2,(H,24,26)

InChI key: InChIKey=ULBPQWIGZUGPHU-UHFFFAOYSA-N

SMILES: C(F)(F)(F)C=1C=2C(=CC=C(N(CC(F)(F)F)CC(F)(F)F)C2)NC(=O)C1

LGD-2226

CAS: 328947-93-9

Formula: C₁₄H₉F₉N₂O

Color and Shape: Neat

Molecular weight: 392.22

Ref: TR-L397615

LGD-2226

CAS: 328947-93-9

LGD-2226 is a designer drug that belongs to the class of selective androgen receptor modulators. It binds to the androgen receptor, which allows it to inhibit cell growth by blocking transcription. LGD-2226 has been shown to be effective in treating metabolic disorders such as obesity and type II diabetes. The drug also has potential for use in the treatment of cancer, possessing low toxicity as well as high efficacy for cancer cells. LGD-2226 induces an apoptotic pathway in human adrenocortical carcinoma cells by inhibiting protein synthesis through inhibition of cyclin D1 expression. This drug has been shown to have a tumour suppressor gene activity, with the ability to induce apoptosis in deficient mice with lung cancer.

Formula: C₁₄H₉F₉N₂O

Purity: Min. 95%

Molecular weight: 392.22 g/mol

Ref: 3D-DNA94793

LGD-2226

CAS: 328947-93-9

LGD-2226: selective oral androgen receptor modulator, EC50: 0.2nM, Ki: 1.5nM. Treats muscle loss, osteoporosis, sexual issues.

Formula: C₁₄H₉F₉N₂O

Purity: 98%

Color and Shape: Solid

Molecular weight: 392.22

Ref: TM-T15749